Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
  • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
  • C07D237/30—Phthalazines
  • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring

Definitions

• the present invention relates to novel hypolipidemic, antihyperglycemic, antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel ⁇ -aryl- ⁇ -oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
• the present invention also relates to a process for the preparation of the above said novel compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
• the present invention also relates to novel intermediates, processes for their preparation and their use in the preparation of compounds of formula (I).
• the compounds of the present invention lower total cholesterol (TC); increase high density lipoprotein (HDL) and decrease low density lipoprotein (LDL), which have beneficial effects on coronary heart disease and atherosclerosis.
• TC total cholesterol
• HDL high density lipoprotein
• LDL low density lipoprotein
• the compounds of general formula (I) are useful in reducing body weight and for the treatment and / or prophylaxis of diseases such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders. These compounds are useful for the treatment of familial hypercholesterolemia, hypertriglyceridemia, lowering of atherogenic lipoproteins, VLDL and LDL.
• the compounds of the present invention can be used for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy and nephropathy.
• the compoimds of general formula (I) are also useful for the treatment and/or prophylaxis of insulin resistance (type II diabetes), leptin resistance, impaired glucose tolerance, dyslipidemia and disorders related to syndrome X such as hypertension, obesity, insulin resistance, coronary heart disease, and other cardiovascular disorders.
• These compounds may also be useful as aldose reductase inhibitors, for improving cognitive functions in dementia, treating diabetic complications, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), inflammatory bowel diseases, osteoporosis, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma and for the treatment of cancer.
• the compounds of the present inventions are useful in the treatment and/or prophylaxis of the above said diseases in combination / concomittant with one or more HMG CoA reductase inhibitors, hypolipidemic / hypolipoproteinemic agents such as fibric acid derivatives, nicotinic acid, cholestyramine, colestipol, probucol.
• Atherosclerosis and other peripheral vascular diseases are the major causes affecting the quality of life of millions of people. Therefore, considerable attention has been directed towards understanding the etiology of hypercholesterolemia and hyperlipidemia and development of effective therapeutic strategies.
• Hypercholesterolemia has been defined as plasma cholesterol level that exceeds an arbitrarily defined value called “normal” level. Recently, it has been accepted that "ideal" plasma levels of cholesterol are much below the "normal” level of cholesterol in general population and the risk of coronary artery disease (CAD) increases as cholesterol level rises above the "optimum” (or “ideal”) value. There is clearly a definite cause and effect-relationship between hypercholesterolemia and CAD, particularly for individuals with multiple risk factors. Most of the cholesterol is present in the esterified forms with various lipoproteins such as Low density lipoprotein (LDL), Intermediate density lipoprotein (IDL), High density lipoprotein (HDL) and partially as Very low density lipoprotein (VLDL).
• LDL Low density lipoprotein
• IDL Intermediate density lipoprotein
• HDL High density lipoprotein
• VLDL Very low density lipoprotein
• Obesity is a disease highly prevalent in affluent societies and in the developing world and is a major cause of morbidity and mortality. It is a state of excess body fat accumulation. The causes of obesity are unclear. It is believed to be of genetic origin or promoted by an interaction between the genotype and environment. Irrespective of the cause, the result is fat deposition due to imbalance between the energy intake versus energy expenditure. Dieting, exercise and appetite suppression have been a part of obesity treatment. There is a need for efficient therapy to fight this disease since it may lead to coronary heart disease, diabetes, stroke, hyperlipidemia, gout, osteoarthritis, reduced fertility and many other psychological and social problems.
• Diabetes and insulin resistance is yet another disease which severely effects the quality of life of a large population in the world.
• Insulin resistance is the diminished ability of insulin to exert its biological action across a broad range of concentrations.
• the body secretes abnormally high amounts of insulin to compensate for this defect; failing which, the plasma glucose concentration inevitably rises and develops into diabetes.
• diabetes mellitus is a common problem and is associated with a variety of abnormalities including obesity, hypertension, hyperlipidemia (J. Clin. Invest., (1985) 75 : 809 - 817; N. Engl. J. Med. (1987) 317 : 350 - 357 ; J. Clin. Endocrinol.
• Hyperlipidemia is the primary cause for cardiovascular (CVD) and other peripheral vascular diseases.
• High risk of CVD is related to the higher LDL (Low Density Lipoprotein) and VLDL (Very Low Density Lipoprotein) seen in hyperlipidemia.
• LDL Low Density Lipoprotein
• VLDL Very Low Density Lipoprotein
• Patients having glucose intolerance / insulin resistance in addition to hyperlipidemia have higher risk of CVD.
• Numerous studies in the past have shown that lowering of plasma triglycerides and total cholesterol, in particular LDL and VLDL and increasing HDL cholesterol help in preventing cardiovascular diseases.
• Peroxisome proliferator activated receptors are members of the nuclear receptor super family.
• the gamma ( ⁇ ) isoform of PPAR (PPAR ⁇ ) has been implicated in regulating differentiation of adipocytes (Endocrinology, (1994) 135: 798-800) and energy homeostasis (Cell, (1995) 83: 803-812), whereas the alpha ( ⁇ ) isoform of PPAR (PPAR ⁇ ) mediates fatty acid oxidation (Trend. Endocrin. Metab., (1993) 4 : 291-296) thereby resulting in reduction of circulating free fatty acid in plasma (Current Biol. (1995) 5: 618 -621).
• PPAR ⁇ agonists have been found useful for the treatment of obesity (WO 97/36579). It has been recently disclosed that the hypolipidemic effect is enhanced when a molecule has both PPAR ⁇ and PPAR ⁇ agonism activity and suggested to be useful for the treatment of syndrome X (WO 97/25042). Synergism between the insulin sensitizer (PPAR ⁇ agonist) and HMG CoA reductase inhibitor has been observed which may be useful for the treatment of atherosclerosis and xanthoma. (EP 0 753 298).
• PPAR ⁇ is consistently expressed in certain cells and activation of this nuclear receptor with PPAR ⁇ agonists would stimulate the terminal differentiation of adipocyte precursors and cause mo ⁇ hological and molecular changes characteristics of a more differentiated, less malignant state (Molecular Cell, (1998), 465-470; Carcinogenesis, (1998), 1949-53 ; Proc. Natl. Acad. Sci., (1997) 94, 237-241) and inhibition of expression of prostate cancer tissue (Cancer Research (1998), 58 ; 3344-3352). This would be useful in the treatment of certain types of cancer, which express PPAR ⁇ and could lead to a quite nontoxic chemotherapy.
• Leptin resistance is a condition wherein the target cells are unable to respond to leptin signal. This may give rise to obesity due to excess food intake and reduced energy expenditure and cause impaired glucose tolerance, type 2 diabetes, cardiovascular diseases and such other interrelated complications.
• Kallen et al Proc. Natl. Acad. Sci., (1996) 93, 5793-5796) have reported that insulin sensitizers which perhaps due to their PPAR agonist expression and lower plasma leptin concentrations.
• compounds having insulin sensitizing property also possess leptin sensitization activity. They lower the circulating plasma leptin concentrations by improving the target cell response to leptin (WO 98/02159).
• R a represents 2-benzoxazolyl or 2- ⁇ yridyl and R represent CF3 s CH2OCH3 or CH3.
• a typical example is ( 1 S)-3-[4-[2-[N-(2-benzoxazolyl]-N- methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoic acid (II f).
• II f iii)
• International Patent Application Nos. WO 94/13650, WO 94/01420 and WO 95/17394 disclose the compounds of general formula (II g)
• R 2 represents OR 3 where R 3 may be alkyl, aralkyl or aryl group and n is integer in the range of 2-6. An example of these compounds is shown in formula (II h)
• the main objective of the present invention is therefore, to provide novel ⁇ -aryl- ⁇ -oxysubstituted alkylcarboxylic acids and their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymo ⁇ hs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them, or their mixtures.
• Another objective of the present invention is to provide novel ⁇ -aryl- ⁇ - oxysubstituted alkylcarboxylic acids and their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymo ⁇ hs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures which may have agonist activity against PPAR ⁇ and / or PPAR ⁇ , and may inhibit HMG CoA reductase, in addition to having agonist activity against PPAR ⁇ and / or PPAR ⁇ .
• Another objective of the present invention is to provide novel ⁇ -aryl- ⁇ - oxysubstituted alkylcarboxylic acids and their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymo ⁇ hs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures having enhanced activities, without toxic effect or with reduced toxic effect.
• Yet another objective of the present invention is to produce a process for the preparation of novel ⁇ -aryl- ⁇ -oxysubstituted alkylcarboxylic acids and their derivatives of the formula (I) as defined above, their analogs, their tautomeric forms, their stereoisomers, their polymo ⁇ hs, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates.
• Still another objective of the present invention is to provide pharmaceutical compositions containing compounds of the general formula (I), their analogs, their derivatives, their tautomers, their stereoisomers, their polymo ⁇ hs, their salts, solvates or their mixtures in combination with suitable carriers, solvents, diluents and other media normally employed in preparing such compositions.
• Another objective of the present invention is to provide novel intermediates, a process for the preparation of the intermediates and a process for preparing novel ⁇ -aryl- ⁇ -oxysubstituted alkylcarboxylic acids and their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymo ⁇ hs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates using these intermediates.
• R 1 , R 2 , R 3 and R 4 may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, monoalkylamino, dialkyamino, arylamino, aralkylamino, acylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, aryloxycarbon
• R represents hydrogen, hydroxy, alkoxy, halogen, acyl, lower alkyl group or unsubstituted or substituted aralkyl or R 7 forms a bond together with R 6 ;
• R 8 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl group;
• R 9 represents hydrogen or unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl group;
• Y represents oxygen or NR , where R represents hydrogen, alkyl, aryl, hydroxyalkyl,
• Suitable groups represented by R 1 - R 4 and the group R 5 when attached to carbon atom may be selected from hydrogen, halogen atom such as fluorine, chlorine, bromine, or iodine; hydroxy, cyano, nitro, formyl; substituted or unsubstituted ( - C 12 )alkyl group, especially, linear or branched ( -C 6 )alkyl group, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-pentyl, iso-pentyl, hexyl and the like; cyclo(C 3 -C 6 )alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; cyclo(C 3 -C 6 )alkoxy
• the aralkoxycarbonylamino group may be substituted; aryloxycarbonylamino group such as NHCOOC 6 H 5 , NCH 3 COOC 6 H 5 , NC 2 H 5 COOC 6 H 5 , NHCOOC 6 H 4 CH 3 , NHCOOC 6 H 4 OCH 3 and the like, the aryloxycarbonylamino group may be substituted; alkoxycarbonylamino group such as NHCOOC 2 H 5 , NHCOOCH 3 and the like, the alkoxycarbonylamino group may be substituted; carboxylic acid or its derivatives such as amides, like CONH 2 , CONHMe, CONMe 2 , CONHEt, CONEt 2 , CONHPh and the like, the carboxylic acid derivatives may be substituted; acyloxy group such as OOCMe, OOCEt, OOCPh and the like, the acyloxy group may be substituted;
• the substituents may be selected from halogen, hydroxy, or nitro or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aralkoxy, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, aryloxy, alkoxycarbonyl, alkylamino, alkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives. These groups are as defined above.
• R 1 - R 4 and R 5 when attached to carbon atom represent halogen atom such as fluorine, chlorine, bromine; alkyl group such as methyl, ethyl, isopropyl, n-propyl, n-butyl; (C 3 -C 6 )cycloalkyl group such as cyclopropyl; aryl group such as phenyl; aralkyl group such as benzyl; (C ⁇ -C 3 )alkoxy, benzyloxy, hydroxy group, acyl or acyloxy groups.
• halogen atom such as fluorine, chlorine, bromine
• alkyl group such as methyl, ethyl, isopropyl, n-propyl, n-butyl
• (C 3 -C 6 )cycloalkyl group such as cyclopropyl
• aryl group such as phenyl
• aralkyl group such as benzyl
• Suitable groups represented by any two of R 1 to R 4 which form the cyclic structure together with the adjacent carbon atoms to which thery are attached may be selected from -OCH 2 O-, -OCH 2 CH 2 O-, -OCOO-, -CH 2 COO-, -OCH 2 CH 2 NH-, - OCH 2 NH-, -OCH 2 CH 2 S-, -NHCH 2 CH 2 O-, -NHCOCH 2 O-, -CH 2 COCH 2 - and the like, preferably -OCH 2 O-and -OCH 2 CH 2 O- groups.
• Suitable R 5 when attached to a nitrogen atom is selected from hydrogen, hydroxy, formyl; substituted or unsubstituted (d-C 12 )alkyl group, especially, linear or branched (C ⁇ -C 6 )alkyl group, such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso- butyl, t-butyl, n-pentyl, iso-pentyl, hexyl and the like; cyclo(C 3 -C 6 )alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; cyclo(C 3 -C 6 )alkyloxy group such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like,
• preferred substituents may be selected from halogen such as fluorine, chlorine; hydroxy, acyl, acyloxy and amino groups.
• R*-R 4 are the same as defined earlier.
• the group represented by Ar includes substituted or unsubstituted groups selected from divalent phenylene, naphthylene, pyridyl, quinolinyl, benzofuryl, benzopyranyl, benzoxazolyl, benzothiazolyl, indolyl, indolinyl, azaindolyl, azaindolinyl, indenyl, dihydrobenzofuryl, dihydrobenzopyranyl, pyrazolyl and the like.
• the substituents on the group represented by Ar include linear or branched optionally halogenated (C ⁇ -C 6 )alkyl, optionally halogenated (C ⁇ -C 3 )alkoxy, halogen, acyl, amino, acylamino, thio, carboxylic and sulfonic acids and their derivatives.
• the substituents are defined as they are for R -R 4 .
• Ar represents a substituted or unsubstituted divalent, phenylene, naphthylene, benzofuryl, indolyl, indolinyl, quinolinyl, azaindolyl, azaindolinyl, benzothiazolyl or benzoxazolyl groups.
• Ar represents a divalent phenylene or naphthylene, which may be unsubstituted or substituted by methyl, halomethyl, methoxy or halomethoxy groups.
• Suitable R 6 includes hydrogen, lower alkyl groups such as methyl, ethyl or propyl; hydroxy, (C ⁇ -C 3 )alkoxy; halogen atom such as fluorine, chlorine, bromine or iodine; aralkyl such as benzyl, phenethyl, which may be unsubstituted or substituted with halogen, hydroxy, (d-C 3 )alkyl, (C ⁇ -C 3 )alkoxy, benzyloxy, acetyl, acetyloxy groups represent a bond.
• Suitable R 7 may be hydrogen, lower alkyl groups such as methyl, ethyl or propyl; hydroxy, (C ⁇ -C 3 )alkoxy; halogen atom such as fluorine, chlorine, bromine, iodine; acyl group such as linear or branched (C 2 -C 10 )acyl group such as acetyl, propanoyl, butanoyl, pentanoyl, benzoyl and the like; aralkyl such as benzyl, phenethyl, which may be unsubstituted or substituted with halogen, hydroxy, (C ⁇ -C 3 )alkyl, (Ci- C 3 )alkoxy, benzyloxy, acetyl or acetyloxy groups or together with R 6 forms a bond.
• halogen atom such as fluorine, chlorine, bromine, iodine
• acyl group such as linear or branched (C 2
• R 6 and R 7 represent hydrogen atom or R 6 and R 7 together represent a bond.
• Suitable groups represented by R 8 may be selected from hydrogen, linear or branched (C 1 -C 16 )alkyl, preferably (d-C 12 )alkyl group such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, pentyl, hexyl, octyl and the like, the alkyl group group may be substituted; (C 3 -C 7 )cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like, the cycloalkyl group may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; heteroaryl group such as pyridyl, thienyl, furyl and the like, the heteroaryl group may be substituted; heteroaralkyl group such as furanmethyl
• the substituents may be selected from halogen, hydroxy, formyl or nitro or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, arylamino, aminoalkyl, aryloxy, alkoxycarbonyl, alkylamino, alkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives. These groups are as defined above.
• Suitable groups represented by R 9 may be selected from hydrogen, linear or branched (C ⁇ -C 16 )alkyl, preferably (C t -C ⁇ 2 )alkyl group such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, pentyl, hexyl, octyl and the like, the (C ⁇ -C ⁇ 6 )alkyl group may be substituted; (C 3 -C 7 )cycloalkyl such as cyclopropyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; aryl group such as phenyl, naphthyl, the aryl group may be substituted; heteroaryl group such as pyridyl, thienyl, furyl and the like, the heteroaryl group may be substituted; heteroaralkyl group such as furanmethyl,
• Suitable groups represented by R 10 may be selected from hydrogen, linear or branched (d-C ⁇ alkyl, preferably (C ⁇ -C ⁇ 2 )alkyl; hydroxy(C ⁇ -C 6 )alkyl; aryl group such as phenyl, naphthyl and the like; aralkyl group such as benzyl, phenethyl and the like; heterocyclyl group such as aziridinyl, pyrrolidinyl, piperidinyl, and the like; heteroaryl group such as pyridyl, thienyl, furyl and the like; heteroaralkyl group such as furanmethyl, pyridinemethyl, oxazolemethyl, oxazolethyl and the like.
• Suitable ring structures formed by R 9 and R 10 together may be selected from pyrrolidinyl, piperidinyl, mo ⁇ holinyl, piperazinyl and the like.
• Suitable n is an integer ranging from 1 to 4, preferably n represents an integer 1 or 2.
• Pharmaceutically acceptable salts forming part of this invention include salts of the carboxylic acid moiety such as alkali metal salts like Li, Na, and K salts, alkaline earth metal salts like Ca and Mg salts, salts of organic bases such as diethanolamine, choline and the like, salts of natural aminoacids such as lysine, arginine, glycine, guanidine and the like, salts of unnatural aminoacids such as D-isomers or substituted aminoacids, ammonium or substituted ammonium salts and aluminum salts.
• alkali metal salts like Li, Na, and K salts
• alkaline earth metal salts like Ca and Mg salts
• salts of organic bases such as diethanolamine, choline and the like
• salts of natural aminoacids such as lysine, arginine, glycine, guanidine and the like
• salts of unnatural aminoacids such as D-isomers or substituted amino
• Salts may include acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulphonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like.
• Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.
• Particularly useful compounds according to the present invention include : ( ⁇ ) Ethyl 2-ethoxy-3-[4-[2-(l-oxo-l ,2-dihydro-2-phthalazinyl)ethoxy]phenyl] propanoate ; (+) Ethyl 2-ethoxy-3-[4-[2-(l-oxo-l,2-dihydro-2-phthalazinyl)ethoxy]phenyl] propanoate; (-) Ethyl 2-ethoxy-3-[4-[2-(l-oxo-l,2-dihydro-2-phthalazinyl)ethoxy]phenyl] propanoate ;
• the compound of general formula (I) where R 6 and R 7 together represent a bond, Y represents oxygen atom, R 1 , R 2 , R 3 , R 4 , R 5 , X, W, R 8 , R 9 , n and Ar are as defined earlier, may be prepared by any of the following routes shown in Scheme I.
• Route 1 The reaction of a compound of the general formula (Hla) where all symbols are as defined earlier with a compound of formula (Ulb), where R 1 ' may be a lower alkyl group and R 8 and R 9 are as defined earlier excluding hydrogen, to yield a compound of general formula (I) defined above, may be carried out in the presence of a base such as alkali metal hydrides like NaH or KH or organolithiums like CH 3 Li, BuLi and the like or alkoxides such as NaOMe, NaOEt, K + BuO " or mixtures thereof.
• the reaction may be carried out in presence of solvents such as THF, dioxane, DMF, DMSO, DME and the like or mixtures thereof.
• HMPA may be used as cosolvent.
• the reaction temperature may range from -78 °C to 50 °C, preferably at a temperature in the range of -10 °C to 30 °C.
• the reaction is more effective under anhydrous conditions.
• the compound of general formula (Ulb) may be prepared according to the procedure described in the literature (Annalen. Chemie, (1996) 53, 699) Alternatively, the compound of formula (I) may be prepared by reacting the compound of formula (Ilia) where all symbols are as defined earlier with Wittig reagents such as Hal " PH 3 P + CH-(OR 8 )CO 2 R 9 under similar reaction conditions as described above.
• Route 2 The reaction of a compound of the general formula (Ilia) where all symbols are as defined earlier with a compound of formula (IIIc) where R 7 represents a hydrogen atom and R and R are as defined earlier may be carried out in the presence of a base.
• the nature of the base is not critical. Any base normally employed for aldol condensation reaction may be employed; bases like metal hydride such as NaH or KH, metal alkoxides such as NaOMe, K + BuO " or NaOEt, metal amides such as LiNH 2 or LiN(iPr) 2 may be used.
• Aprotic solvent such as THF, ether or dioxane may be used.
• the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar, or He and the reaction is more effective under anhydrous conditions. Temperature in the range of -80 °C to 35 °C may be used.
• the ⁇ -hydroxy product initially produced may be dehydrated under conventional dehydration conditions such as treating with pTSA in solvents such as benzene or toluene.
• solvents such as benzene or toluene.
• the nature of solvent and dehydrating agent is not critical.
• Temperature in the range of 20 °C to reflux temperature of the solvent used may be employed, preferably at reflux temperature of the solvent by continuous removal of water using a Dean Stark water separator.
• Route 3 The reaction of compound of formula (Ille) where all symbols are as defined earlier and L 1 represents a leaving group such as as halogen atom, p-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like, preferably a halogen atom with a compound of formula (Hid) where R 6 and R 7 together represent a bond and R 8 , R 9 and Ar are as defined earlier to produce a compound of the formula (I) defined above may be carried out in the presence of aprotic solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
• aprotic solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
• the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar, or He.
• the reaction may be effected in the presence of a base such as K2CO3, Na2CO3 or NaH or mixtures thereof.
• Acetone may be used as solvent when Na 2 CO 3 or K 2 CO 3 is used as a base.
• the reaction temperature may range from 0 °C - 120 °C, preferably at a temperature in the range of 30 °C - 100 °C.
• the duration of the reaction may range from 1 to 24 hours, preferably from 2 to 12 hours.
• the compound of formula (Hid) can be prepared according to known procedure by a Wittig Horner reaction between the protected hydroxy aryl aldehyde such as benzyloxy aryl aldehyde and compound of formula (Ulb), followed by the reduction of double bond and deprotection.
• Route 4 The reaction of a compound of general formula (Illg) where all symbols are as defined earlier with a compound of general formula (Illf) where R 6 , R 7 together represent a bond and all other symbols are as defined earlier and L 1 is a leaving group such as halogen atom, p-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like, preferably a halogen atom to produce a compound of general formula (I) defined above where the -(CH 2 ) n -O- is attached through nitrogen atom may be carried out in the presence of solvents such as DMSO, DMF, DME, THF, dioxane, ether and the like or a combination thereof.
• solvents such as DMSO, DMF, DME, THF, dioxane, ether and the like or a combination thereof.
• the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar or He.
• the reaction may be effected in the presence of a base such as alkalis like sodium hydroxide or potassium hydroxide; alkali metal carbonates like sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydride or potassium hydride; organometallic bases like n-butyl lithium; alkali metal amides like sodamide or mixtures thereof.
• the amount of base may range from 1 to 5 equivalents, based on the amount of the compound of formula (Illg), preferably the amount of base ranges from 1 to 3 equivalents.
• Phase transfer catalysts such as tetraalkylammonium halide or hydroxide may be added. Additives like alkali metal halides such as LiBr may be used.
• the reaction may be carried out at a temperature in the range of 0 °C to 150 °C, preferably at a temperature in the range of 15 °C to 100 °C.
• the duration of the reaction may range from 0.25 to 48 hours, preferably from 0.25 to 12 hours.
• Route 5 The reaction of compound of general formula (Illh) where all symbols are as defined earlier with a compound of general formula (Hid) where R 6 and R 7 together represent a bond and R 8 , R 9 and Ar are as defined earlier may be carried out using suitable coupling agents such as dicyclohexyl urea, triarylphosphine/dialkylazadicarboxylate such as PPh 3 / DEAD and the like.
• the reaction may be carried out in the presence of solvents such as THF, DME, CH 2 C1 2 , CHC1 3 , toluene, acetonitrile, carbontetrachloride and the like.
• the inert atmosphere may be maintained by using inert gases such as N , Ar or He.
• the reaction may be effected in the presence of DMAP, HOBT and they may be used in the range of 0.05 to 2 equivalents, preferably 0.25 to 1 equivalents.
• the reaction temperature may be in the range of 0 °C to 100 °C, preferably at a temperature in the range of 20 °C to 80 °C.
• the duration of the reaction may range from 0.5 to 24 hours, preferably from 6 to 12 hours.
• the reaction may be carried out in the presence of aprotic solvents such as THF, dioxane, DMF, DMSO, DME and the like or mixtures thereof.
• HMPA may be used as cosolvent.
• the reaction temperature may range from -78 °C to 100 °C, preferably at a temperature in the range of -10 °C to 50 °C.
• the compound of the general formula (I) where R 6 represents hydroxy, alkoxy, halogen, lower alkyl or unsubstituted or substituted aralkyl group; R 7 represents hydroxy, alkoxy, halogen, acyl, lower alkyl or unsubstituted or substituted aralkyl group; R 1 , R , R , R , R , X, W, R , R 9 , n, and Ar as defined earlier and Y represents oxygen atom can be prepared by one or more of the processes shown in Scheme - II:
• Route 7 The reduction of compound of the formula (TVa) which represents a compound of formula (I) where R 6 and R 7 together represent a bond and Y represents an oxygen atom and all other symbols are as defined earlier, may be obtained as described
• the reaction may also be carried out by employing metal solvent reduction such as magnesium in alcohol or sodium amalgam i n alcohol, preferably methanol.
• the hydrogenation may be carried out in the presence of metal catalysts containing chiral ligands to obtain a compound of formula (I) in optically active form.
• the metal catalyst may contain Rhodium, Ruthenium, Indium and the like.
• the chiral ligands may preferably be chiral phosphines such as (2S,3S)- bis(diphenylphosphino)butane, 1 ,2-bis(diphenylphosphino)ethane, 1 ,2-bis(2- methoxyphenylphosphino)ethane, (-)-2,3-isopropy_idene-2,3-dihydroxy-l ,4- bis(diphenylphosphino) butane and the like.
• Any suitable chiral catalyst may be employed which would give required optical purity of the product (I) (Ref : Principles of Asymmetric Synthesis, Tet. Org. Chem. Series Vol 14, pp311-316, Ed. Baldwin J. E.).
• Route 8 The reaction of compound of formula (IVb) where R 9 is as defined earlier excluding hydrogen and all other symbols are as defined earlier and L 2 is a leaving group such as halogen atom with an alcohol of general formula (IVc), where R 8 is as defined earlier excluding hydrogen to produce a compound of the formula (I) defined earlier may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
• solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
• the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar, or He.
• the reaction may be effected in the presence of a base such as KOH, NaOH, NaOMe, NaOEt, K + BuO " or NaH or mixtures thereof.
• Phase transfer catalysts such as tetraalkylammonium halides or hydroxides may be employed.
• the reaction temperature may range from 20 °C - 120 °C, preferably at a temperature in the range of 30 °C - 100 °C.
• the duration of the reaction may range from 1 to 12 hours, preferably from 2 to 6 hours.
• the compound of general formula (IVb) and its preparation has been disclosed in international application No. US98/07285.
• Route 9 The reaction of compound of formula (Ille) defined earlier with a compound of formula (Hid) where all symbols are as defined earlier to produce a compound of the formula (I) where all symbols are as defined above, may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
• the reaction may be carried out in an inert atmosphere which is maintained by using inert gases such as N2, Ar or He.
• the reaction may be effected in the presence of a base such as K2CO3, Na2CO3 or NaH or mixtures thereof.
• Acetone may be used as a solvent when K2CO3 or Na2CO3 is used as a base.
• the reaction temperature may range from
• the compound of formula (Hid) may be prepared by Wittig Horner reaction between the protected hydroxyaryl aldehyde and compound of formula (Ulb) followed by reduction of the double bond and deprotection. Alternatively, the compound of formula (Hid) may be prepared by following a procedure disclosed in WO 94/01420.
• Route 10 The reaction of compound of general formula (Illh) defined earlier with a compound of general formula (Hid) where all symbols are as defined earlier to produce a compound of the formula (I) where all symbols are as defined above may be carried out using suitable coupling agents such as dicyclohexyl urea, triarylphosphine/dialkylazadicarboxylate such as PPh 3 / DEAD and the like.
• the reaction may be carried out in the presence of solvents such as THF, DME, CH 2 C1 2 , CHC1 3 , toluene, acetonitrile, carbon tetrachloride and the like.
• the inert atmosphere may be maintained by using inert gases such as N 2 , Ar or He.
• the reaction may be effected in the presence of DMAP, HOBT and they may be used in the range of 0.05 to
• the reaction temperature may be in the range of 0 °C to 100 °C, preferably at a temperature in the range of 20 °C to 80 °C.
• the duration of the reaction may range from 0.5 to 24 hours, preferably from 6 to 12 hours.
• Route 11 The reaction of compound of formula (IVd) which represents a compound of formula (I) where all symbols are as defined earlier with a compound of formula (IVe) where R 8 represents unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl and L is a leaving group such as halogen atom, may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like.
• solvents such as THF, DMF, DMSO, DME and the like.
• the inert atmosphere may be maintained by using inert gases such as N2, Ar or He.
• the reaction may be effected in the presence of a base such as KOH, NaOH, NaOMe, K + BuO " , NaH and the like.
• Phase transfer catalyst such as tetraalkylammoniumhalides or hydroxides may be employed.
• the reaction temperature may range from 20 °C to 150 °C, preferably at a temperature in the range of 30 °C to 100 °C.
• the duration of the reaction may range from 1 to 24 hours, preferably from 2 to 6 hours.
• the compound of formula (IVd) represents compound of formula (I) where R 8 represents H and Y represents oxygen atom.
• Route 12 The reaction of a compound of the general formula (Ilia) as defined earlier with a compound of formula (Ille) where R 7 , R 8 and R 9 are as defined earlier may be carried out under conventional conditions.
• the base is not critical. Any base normally employed for aldol condensation reaction may be employed, metal hydride such as NaH, or KH; metal alkoxides such as NaOMe, K l BuO " or NaOE;, metal amides such as LiNH 2 or LiN(iPr) 2 . Aprotic solvent such as THF may be used. Inert atmosphere may be employed such as argon and the reaction is more effective under anhydrous conditions. Temperature in the range of -80 °C to 25 °C may be used.
• the ⁇ -hydroxy aldol product may be dehydroxylated using conventional methods, conveniently by ionic hydrogenation technique such as by treating with a trialkyl silane in the presence of an acid such as trifluoroacetic acid.
• Solvent such as CH C1 2 may be used.
• the reaction proceeds at 25 °C. Higher temperature may be employed if the reaction is slow.
• Route 13 The reaction of a compound of general formula (Illg) where all symbols are as defined earlier with a compound of general formula (lllf) where L 1 is a leaving group such as halogen atom, p-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like, preferably a halogen atom, all other symbols are as defined earlier to produce a compound of general formula (I) defined above where the -(CH 2 ) n -O- is attached through nitrogen atom may be carried out in the presence of solvents such as DMSO, DMF, DME, THF, dioxane, ether and the like or a combination thereof.
• solvents such as DMSO, DMF, DME, THF, dioxane, ether and the like or a combination thereof.
• the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N2, Ar or He.
• the reaction may be effected in the presence of a base such as alkalis like sodium hydroxide or potassium hydroxide; alkali metal carbonates like sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydride or potassium hydride; organometallic bases like n-butyl lithium; alkali metal amides like sodamide or mixtures thereof.
• the amount of base may range from 1 to 5 equivalents, based on the amount of the compound of formula (Illg), preferably the amount of base ranges from 1 to 3 equivalents.
• the reaction may be carried out at a temperature in the range of 0 °C to 150 °C, preferably at a temperature in the range of
• the duration of the reaction may range from 0.25 to 24 hours, preferably from 0.25 to 12 hours.
• Route 15 The reaction of a compound of formula (IVg) where R 9 is as defined earlier excluding hydrogen all symbols are as defined earlier with a compound of formula (IVc) where R is as defined earlier excluding hydrogen to produce a compound of formula (I) (by a rhodium carbenoid mediated insertion reaction) may be carried out in the presence of rhodium (II) salts such as rhodium (II) acetate.
• rhodium (II) salts such as rhodium (II) acetate.
• the reaction may be carried out in the presence of solvents such as benzene, toluene, dioxane, ether, THF and the like or a combination thereof or when practicable in the presence of R 8 OH as solvent at any temperature providing a convenient rate of formation of the required product, generally at an elevated temperature, such as reflux temperature of the solvent.
• solvents such as benzene, toluene, dioxane, ether, THF and the like or a combination thereof or when practicable in the presence of R 8 OH as solvent at any temperature providing a convenient rate of formation of the required product, generally at an elevated temperature, such as reflux temperature of the solvent.
• the inert atmosphere may be maintained by using inert gases such as N 2 , Ar or He.
• the duration of the reaction may range from 0.5 to 24 h, preferably from 0.5 to 6 h.
• the compound of formula (I) where R 9 represents hydrogen atom may be prepared by hydrolysing using conventional methods, a compound of formula (I) where R 9 represents all groups defined earlier except hydrogen.
• the hydrolysis may be carried out in the presence of a base such as Na 2 CO 3 and a suitable solvent such as methanol, ethanol and the like or mixtures thereof.
• the reaction may be carried out at a temperature in the range of 20 °C - 40 °C, preferably at 25 °C - 30 °C.
• the reaction time may range from 2 to 12 h, preferably from 4 to 8 h.
• the compound of general formula (I) where Y represents oxygen and R 9 represents hydrogen or lower alkyl groups as defined earlier may be converted to compound of formula (I), where Y represents NR 10 by reaction with appropriate amines of the formula NHR 9 R 10 , where R 9 and R 10 are as defined earlier.
• mixed anhydrides may be prepared from compound of formula (I) where YR 9 represents OH and all other symbols are as defined earlier by treating with acid halides such acetyl chloride, acetyl bromide, pivaloyl chloride and the like.
• the reaction may be carried in the presence of suitable base such as pyridine, triethylamine, diisopropyl ethyl amine and the like.
• Solvents such as halogenated hydrocarbons like CHC1 3 or CH 2 C1 2 , hydrocarbons such as benzene, toluene, xylene and the like may be used.
• the reaction may be carried out at a temperature in the range of-40°C to 40 °C, preferably 0 °C to 20 °C.
• the acid halide or mixed anhydride thus prepared may further be treated with appropriate amines of the formula NHR 9 R 10 , where R 9 and R 10 are as defined earlier.
• R l , R 2 , R 3 and R 4 may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, monoalkylamino, dialkylamino, arylamino, aralkylamino, acylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, aryloxycarbon
• the reaction of a compound of formula (Hla) where all symbols are as defined earlier with a compound of formula (IVh) where R 8 is as defined earlier excluding hydrogen and Hal represent a halogen atom such as Cl, Br or I to produce a compound of formula (IVi) may be carried out under conventional conditions in the presence of a base.
• the base is not critical. Any base normally employed for Wittig reaction may be employed, metal hydride such as NaH or KH; metal alkoxides such as NaOMe, K'BuO " or NaOEt; metal amides such as LiNH 2 or LiN(iPr) 2 .
• Aprotic solvent such as THF, DMSO, dioxane, DME and the like may be used. Mixture of solvents may be used.
• HMPA may be used as cosolvent.
• Inert atmosphere may be employed such as argon and the reaction is more effective under anhydrous conditions. Temperature in the range of - 80 °C to 100 °C may be used.
• the compound of (TVi) where all symbols are as defined earlier and R is as defined earlier excluding hydrogen may be converted to a compound of formula (IVj) where R 6 and R 7 represent hydrogen atoms and all other symbols are as defined earlier, by treating with an alcohol of formula R 8 OH where R 8 represents unsubstituted or substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocyclyl, heteroaryl or heteroaralkyl under anhydrous conditions in the presence of a strong anhydrous acid such as p-toluenesulfonic acid.
• R 1 , R 2 , R 3 and R 4 may be the same or different and represent hydrogen, halogen, hydroxy, cyano, nitro, formyl or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkyloxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaryloxy, heteroaralkyl, heteroaralkoxy, acyl, acyloxy, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, amino, monoalkylamino, dialkyamino, arylamino, aralkylamino, acylamino, aminoalkyl, hydroxyalkyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, thioalkyl, alkylthio, aryloxycarbon
• the compound of formula (Wg) where all other symbols are as defined earlier may be prepared by reacting a compound of formula (F/k)
• R 7 is hydrogen atom and all other symbols are as defined earlier, with an appropriate diazotizing agent.
• the diazotization reaction may be under conventional conditions.
• a suitable diazotizing agent is an alkyl nitrile, such as iso-amyl nitrile.
• the reaction may be carried out in presence of solvents such as THF, dioxane, ether, benzene and the like or a combination thereof. Temperature in the range of -50 °C to 80 °C may be used.
• the reaction may be carried out in an inert atmosphere which may be maintained by using inert gases such as N 2 , Ar or He.
• the duration of the reaction may range from 1 to 24 h, preferably, 1 to 12 h.
• the compound of formula (IVk) may also be prepared by a reaction between (Ille) where all symbols are as defined earlier and a compound of formula (IVI)
• reaction of compound of formula (Ille) where all symbols are as defined earlier and a compound of formula (IVI) where all symbols are as defined earlier may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
• solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof.
• the reaction may be carried out in an inert atmosphere which is maintained by using inert gases such as N2, Ar or He.
• the reaction may be effected in the presence of a base such as K2CO3, Na2CO3 or NaH or mixtures thereof.
• Acetone may be used as a solvent when K2CO3 or Na2CO3 is used as a base.
• the reaction temperature may range from 20 °C - 120 °C, preferably at a temperature in the range of
• the duration of the reaction may range from 1 to 24 hours, preferably from 2 to 12 hours.
• the pharmaceutically acceptable salts are prepared by reacting the compound of formula (I) with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, dioxane, isopropanol, ethanol and the like. Mixture of solvents may be used.
• Preparation of pharmaceutically acceptable salts of organic bases may be prepared by treatment with organic bases like lysine, arginine, glycine, guanidine, diethanolamine, choline, guanidine and their derivatives.
• acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid, salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane etc. Mixture of solvents may also be used.
• stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods.
• Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like.
• polymo ⁇ hs of compound of general formula (I) forming part of this invention may be prepared by crystallization of compound of formula (I) under different conditions.
• polymo ⁇ hs may be prepared by using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; or various modes of cooling, ranging from very fast to very slow cooling during crystallizations.
• Polymo ⁇ hs may also be obtained by heating or melting the compound followed by gradual or fast cooling.
• the presence of polymo ⁇ hs may be determined by solid probe nmr spectroscopy, ir spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.
• the present invention also provides a pharmaceutical composition, containing the compounds of the general formula (I), as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymo ⁇ hs, their pharmaceutically acceptable salts or their pharmaceutically acceptable solvates in combination with the usual pharmaceutically employed carriers, diluents and the like, useful for the treatment and / or prophylaxis of diseases such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders.
• diseases such as hypertension, coronary heart disease, atherosclerosis, stroke, peripheral vascular diseases and related disorders.
• These compounds are useful for the treatment of familial hypercholesterolemia, hypertriglyceridemia, lowering of atherogenic lipoproteins, VLDL and LDL.
• the compounds of the present invention can be used for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy.
• the compounds of general formula (I) are also useful for the treatment / prophylaxis of insulin resistance (type II diabetes), leptin resistance, impaired glucose tolerance, dyslipidemia, disorders related to syndrome X such as hypertension, obesity, insulin resistance, coronary heart disease, and other cardiovascular disorders.
• These compounds may also be useful as aldose reductase inhibitors, for improving cognitive functions in dementia, treating diabetic complications, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), inflammatory bowel diseases, osteoporosis, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma and for the treatment of cancer.
• PCOS polycystic ovarian syndrome
• the compounds of the present inventions are useful in the treatment and / or prophylaxis of the above said diseases in combination / concomittant with one or more HMG CoA reductase inhibitors, hypolipidemic / hypolipoproteinemic agents such as fibric acid derivatives, nicotinic acid, cholestyramine, colestipol, probucol.
• HMG CoA reductase inhibitors, hypolipidemic / hypolipoproteinemic agents such as fibric acid derivatives, nicotinic acid, cholestyramine, colestipol, probucol.
• the compounds of the present invention in combination with HMG CoA reductase inhibitors, hypolipidemic / hypolipoproteinemic agents can be administered together or within such a period to act synergistically.
• the HMG CoA reductase inhibitors may be selected from those used for the treatment or prevention of hyperlipidemia such as lovastatin, provastatin, simvastatin, fluvastatin, atorvastatin, cerivastatin and their analogs thereof.
• Suitable fibric acid derivative may be gemfibrozil, clofibrate, fenofibrate, ciprofibrate, benzafibrate and their analogs thereof.
• the pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, and may contain flavourants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions.
• compositions typically contain from 1 to 20 %, preferably 1 to 10 % by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents.
• the compound of the formula (I) as defined above are clinically administered to mammals, including man, via either oral or parenteral routes. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or abso ⁇ tion following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally.
• the dosage is in the range of about 0.01 to about 50 mg / kg body weight of the subject per day or preferably about 0.01 to about 30 mg / kg body weight per day administered singly or as a divided dose.
• the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage.
• Suitable pharmaceutically acceptable carriers include solid fillers or diluents and sterile aqueous or organic solutions.
• the active compound will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above.
• the compounds can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like.
• the pharmaceutical compositions may, if desired, contain additional components such as flavourants, sweeteners, excipients and the like.
• the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions.
• solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds.
• the injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.
• the invention is explained in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.
• the title compound (0.5 g, 32 %) was prepared as an oil from 2-(2-bromoethyl)-4- methyl-l(2H)phthalazinone (1.0 g, 3.7 mmol), ethyl 2-ethoxy-3-(4- hydroxyphenyl)propanoate (0.89 g, 3.7 mmol) and anhydrous K 2 CO 3 (1.0 g, 7.4 mmol) by a similar procedure to that described in example 1.
• the title compound was obtained as an oil (1.0 g, 41 %) from 2-(2-bromoethyl)-l(2H) phthalazinone (1.63 g, 6.4 mmol), ethyl 2-hydroxy-3-(4-hydroxyphenyl)propanoate (DE 2 625 163) (1.35 g, 6.4 mmol) and anhydrous potassium carbonate (1.8 g, 12.8 mmol) by a similar procedure to that described in example 1.
• the title compound (0.28 g, 45 %) was obtained as an oil from 6-methoxy- l(2H)phthalazinone (0.25 g, 1.42 mmol), ethyl 2-ethoxy-[4-(2- bromoethoxy)phenyl]propanoate (0.54 g, 1.56 mmol) and NaH (95 %, 55 mg, 2.13 mmol) by a similar procedure to that described in example 6.
• the title compound (0.58 g, 50 %) was obtained as an oil from 6-chloro- l(2H)phthalazinone (0.45 g, 2.50 mmol), ethyl 2-ethoxy-[4-(2- bromoethoxy)phenyl]propanoate (0.94 g, 2.74 mmol) and NaH (95 %, 0.1 g, 3.75 mmol) by a similar procedure to that described in example 6.
• the title compound (0.52 g, 50 %) was obtained as an oil from 6,7-dimethoxy- l(2H)phthalazinone (0.5 g, 2.43 mmol), ethyl 2-ethoxy-[4-(2- bromoethoxy)phenyl]propanoate (92 mg, 2.67 mmol) and NaH (95 %, 95 mg, 3.64 mmol) by a similar procedure to that described in example 6.
• the title compound (0.38 g, 54 %) was obtained as an oil from 6,7-(l,3)-dioxolo- l(2H)phthalazinone (0.3 g, 1.57 mmol), ethyl 2-ethoxy-[4-(2- bromoethoxy)phenyl]propanoate (0.6 g, 1.73 mmol) and NaH (95 %, 60 mg, 2.35 mmol) by a similar procedure to that described in example 6.
• the title compound was obtained (0.8 g, 43 %) as an oil from 6-methyl- l(2H)phthalazinone (0.71 g, 4.43 mmol), ethyl 2-ethoxy-[4-(2- bromoethoxy)phenyl]propanoate (1.83 g, 5.3 mmol) and NaH (95 %, 0.17 g, 6.84 mmol) by a similar procedure to that described in example 6.
• the aqueous layer was acidified with dilute HC1 (6N) and extracted with ethyl acetate. The extracts were washed with water and then with brine; dried over anhydrous Na SO 4 and the solvent was evaporated to obtain a liquid which slowly became a white solid, m.p. I l l °C.
• the title compound (0.21 g, 70 %) was obtained from ( ⁇ ) 2-hydroxy-3-[4-[2-(l-oxo-l,2- dihydro-2-phthalazinyl)ethoxy]phenyl]propanoic acid (0.2 g, 0.565 mmol) (obtained from example 15), benzyl bromide (0.19 g, 1.13 mmol) and NaH (27 mg, 1.13 mmol) by a similar procedure to that described in example 18.
• reaction mixture was allowed to stir at room temperature for 30 min until all the acid was converted to mixed anhydride (checked by TLC), after which L(+)-valinol (0.15 g, 1.44 mmol) and dry triethylamine (0.33 g,3.3 mmol) in 5 mL of dry dichloromethane was added. After stirring the reaction mixture at room temperature (about 25 °C) for 4 h, water was added and the mixture was extracted with dichloromethane. The organic extracts were washed with water, brine, dried over anhydrous Na SO 4 and evaporated.
• the mixture was extracted with ethyl acetate and the organic extracts were washed with water, brine, dried over Na 2 SO and evaporated to give an oil (0.33 g, 63.4 %).
• the oil was crystallised by triturating with diethyl ether to give white solid, which contained two polymo ⁇ hs, with DSC endotherms at 104 °C and 121 °C.
• brine means sodium chloride salt solution.
• the compounds of the present invention lowered random blood sugar level, triglyceride, total cholesterol, LDL, VLDL, free fatty acids and increased HDL. This was demonstrated by in vitro as well as in vivo animal experiments.
• Ligand binding domain of hPPAR ⁇ was fused to DNA binding domain of Yeast transcription factor GAL4 in eucaryotic expression vector.
• superfect Qiagen, Germany
• HEK-293 cells were transfected with this plasmid and a reporter plasmid harboring the luciferase gene driven by a GAL4 specific promoter.
• Compound was added at different concentrations after 42 hrs of transfection and incubated overnight.
• Luciferase activity as a function of compound binding/activation capacity of PPAR ⁇ was measured using Packard Luclite kit (Packard, USA) in Top Count (Ivan Sadowski, Brendan Bell, Peter Broag and Melvyn Hollis. Gene. 1992. 118 : 137 -141; Superfect Transfection Reagent Handbook. February, 1997. Qiagen, Germany).
• Ligand binding domain of hPPAR ⁇ l was fused to DNA binding domain of Yeast transcription factor GAL4 in eucaryotic expression vector.
• HEK-293 cells were transfected with this plasmid and a reporter plasmid harboring the luciferase gene driven by a GAL4 specific promoter.
• Compoimd was added at 1 ⁇ M concentration after 48 hrs of transfection and incubated overnight.
• Luciferase activity as a function of drug binding/activation capacity of PPAR ⁇ l was measured using Packard Luclite kit (Packard, USA) in Packard Top Count (Ivan Sadowski, Brendan Bell, Peter Broag and Melvyn Hollis. Gene. 1992. 118 : 137 -141; Guide to Eukaryotic Transfections with Cationic Lipid Reagents. Life Technologies, GIBCO BRL, USA).
• Liver microsome bound reductase was prepared from 2% cholestyramine fed rats at mid-dark cycle. Spectrophotometric assays were carried out in 100 mM KH 2 PO 4 , 4 mM DTT, 0.2 mM NADPH, 0.3 mM HMG CoA and 125 ⁇ g of liver microsomal enzyme. Total reaction mixture volume was kept as 1 ml. Reaction was started by addition of HMG CoA. Reaction mixture was incubated at 37 °C for 30 min and decrease in absorbance at 340 nm was recorded. Reaction mixture without substrate was used as blank (Goldstein, J. L and Brown, M. S. Progress in understanding the LDL receptor and HMG CoA reductase, two membrane proteins that regulate the plasma cholesterol. J. Lipid Res. 1984, 25: 1450 - 1461). The test compounds inhibited the HMG CoA reductase enzyme.
• Efficacy in genetic models Mutation in colonies of laboratory animals and different sensitivities to dietary regimens have made the development of animal models with non-insulin dependent diabetes and hyperlipidemia associated with obesity and insulin resistance possible. Genetic models such as db/db and ob/ob (Diabetes, (1982) 31(1) : 1- 6) mice and zucker fa/fa rats have been developed by the various laboratories for understanding the pathophysiology of disease and testing the efficacy of new antidiabetic compounds (Diabetes, (1983) 32: 830-838 ; Annu. Rep. Sankyo Res. Lab. (1994). 46 : 1-57).
• the homozygous animals C57 BL/KsJ-db/db mice developed by Jackson Laboratory, US, are obese, hyperglycemic, hyperinsulinemic and insulin resistant (J. Clin. Invest., (1990) 85 : 962-967), whereas heterozygous animals are lean and normoglycemic.
• db/db model a mouse progressively develops insulinopenia with age, a feature commonly observed in late stages of human type II diabetes when blood sugar levels are insufficiently controlled.
• the state of pancreas and its course vary according to the models. Since this model resembles that of type II diabetes mellitus, the compounds of the present invention were tested for blood sugar and triglycerides lowering activities.
• mice of 8 to 14 weeks age having body weight range of 35 to 60 grams, bred at Dr. Reddy's Research Foundation (DRF) animal house, were used in the experiment.
• the mice were provided with standard feed (National Institute of Nutrition (NIN), India) and acidified water, ad libitum.
• the animals having more than 350 mg / dl blood sugar were used for testing.
• the number of animals in each group was 4.
• Test compounds were suspended on 0.25 % carboxymethyl cellulose and administered to test group at a dose of 0.1 mg to 30 mg / kg through oral gavage daily for 6 days.
• the control group received vehicle (dose 10 ml / kg).
• the blood samples were collected one hour after administration of test compounds / vehicle for assessing the biological activity.
• the random blood sugar and triglyceride levels were measured by collecting blood (100 ⁇ l) through orbital sinus, using heparinised capillary in tubes containing EDTA which was centrifuged to obtain plasma.
• the plasma glucose and triglyceride levels were measured spectrometrically, by glucose oxidase and glycerol-3- PO 4 oxidase/peroxidase enzyme (Dr. Reddy's Lab. Diagnostic Division Kits, India) methods respectively.
• the blood sugar and triglycerides lowering activities of the test compound was calculated according to the formula.
• mice were obtained at 5 weeks of age from Bomholtgard, Demark and were used at 8 weeks of age.
• Zucker fa/fa fatty rats were obtained from IffaCredo, France at 10 weeks of age and were used at 13 weeks of age.
• the animals were maintained under 12 hour light and dark cycle at 25 + 1 °C.
• Animals were given standard laboratory chow (NIN, India) and water, ad libitum (Fujiwara, T., Yoshioka, S., Yoshioka, T., Ushiyama. I, and Horikoshi, H. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes. 1988. 37 : 1549 - 1558).
• the test compoimds were administered at 0.1 to 30 mg/kg/day dose for 9 days.
• the control animals received the vehicle (0.25 % carboxymethylcellulose, dose 10 ml kg) through oral gavage.
• the blood samples were collected in fed state 1 hour after drug administration on 0 and 9 day of treatment.
• the blood was collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample was separated for triglyceride, glucose, free fatty acid, total cholesterol and insulin estimations. Measurement of plasma triglyceride, glucose, total cholesterol were done using commercial kits (Dr. Reddy's Laboratory, Diagnostic Division, India).
• the plasma free fatty acid was measured using a commercial kit form Boehringer Mannheim, Germany.
• the plasma insulin was measured using a RIA kit (BARC, India). The reduction of various parameters examined are calculated according to the formula shown below.
• ob/ob mice oral glucose tolerance test was performed after 9 days treatment. Mice were fasted for 5 hrs and challenged with 3 gm/kg of glucose orally. The blood samples were collected at 0, 15, 30, 60 and 120 min for estimation of plasma glucose levels.
• the experimental results from the db/db mice, ob/ob mice, Zucker fa/fa rats suggest that the novel compounds of the present invention also possess therapeutic utility as a prophylactic or regular treatment for diabetes, obesity, cardiovascular disorders such as hypertension, hyperlipidaemia and other diseases; as it is known from the literature that such diseases are interrelated to each other.
• Blood glucose level and triglycerides are also lowered at doses greater than 10 mg/kg. Normally, the quantum of reduction is dose dependent and plateaus at certain dose.
• test compounds were administered orally at a dose 0.1 to 30 mg/kg/day for 3 days.
• Control group was treated with vehicle alone (0.25 % Carboxymethylcellulose; dose 10 ml/kg).
• the blood samples were collected in fed state 1 hour after drug administration on 0 and 3 day of compound treatment.
• the blood was collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample was separated for total cholesterol, HDL and triglyceride estimations. Measurement of plasma triglyceride, total cholesterol and HDL were done using commercial kits (Dr. Reddy's Laboratory, Diagnostic Division, India). LDL and VLDL cholesterol were calculated from the data obtained for total cholesterol, HDL and triglyceride. The reduction of various parameters examined are calculated according to the formula.
• Plasma triglyceride and total cholesterol lowering activity in Swiss albino mice and Guinea pigs Male Swiss albino mice (SAM) and male Guinea pigs were obtained from NIN and housed in DRF animal house. All these animals were maintained under 12 hour light and dark cycle at 25 ⁇ 1 °C. Animals were given standard laboratory chow (NIN, India) and water, ad libitum. SAM of 20 - 25 g body weight range and Guinea pigs of 500 - 700 g body weight range were used (Oliver, P., Plancke, M. O., Marzin, D., Clavey, V., Sauzieres, J and Fruchart, J. C.
• test compoimds were administered orally to Swiss albino mice at 0.3 to 30 mg/kg/day dose for 6 days. Control mice were treated with vehicle (0.25% Carboxymethylcellulose; dose 10 ml/kg). The test compoimds were administered orally to Guinea pigs at 0.3 to 30 mg/kg/day dose for 6 days. Control animals were treated with vehicle (0.25%o Carboxymethylcellulose; dose 5 ml/kg). The blood samples were collected in fed state 1 hour after drug administration on 0 and 6 day of treatment.
• the blood was collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample was separated for triglyceride and total cholesterol (Wieland, O. Methods of Enzymatic analysis. Bergermeyer, H. O., Ed., 1963. 211 - 214; Trinder, P. Ann. Clin. Biochem. 1969. 6 : 24 - 27). Measurement of plasma triglyceride, total cholesterol and HDL were done using commercial kits (Dr. Reddy's Diagnostic Division, India).
• LDL and VLDL cholesterol levels were calculated according to the formula :
• Triglyceride LDL cholesterol in mg/dl [ Total cholesterol - HDL cholesterol - ] mg/dl
• VLDL cholesterol in mg/dl [Total cholesterol-HDL cholesterol-LDL cholesterol] mg/dl

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Life Sciences & Earth Sciences (AREA)
• Diabetes (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Physical Education & Sports Medicine (AREA)
• Urology & Nephrology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Child & Adolescent Psychology (AREA)
• Emergency Medicine (AREA)
• Vascular Medicine (AREA)
• Ophthalmology & Optometry (AREA)
• Dermatology (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Applications Claiming Priority (5)

Publications (1)

Family

ID=26324757

Family Applications (1)

Country Status (4)

Cited By (2)

Families Citing this family (41)

Family Cites Families (2)

• 1999
  • 1999-01-25 EP EP99900271A patent/EP1051403A1/de not_active Withdrawn
  • 1999-01-25 JP JP2000529318A patent/JP2002501909A/ja active Pending
  • 1999-01-25 WO PCT/IB1999/000131 patent/WO1999038850A1/en not_active Application Discontinuation
  • 1999-01-25 AU AU18879/99A patent/AU1887999A/en not_active Abandoned

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events